Introduction
Carcinoid tumors are relatively uncommon, slow growing neuroendocrine tumors (NETs) arising from enterochromaffin cells and predominantly found in the gastrointestinal (GI) tract (1, 2) . The overall incidence of carcinoid tumors is approximately 2 cases per 100 000 people, but the actual incidence is thought to be higher (3, 4) . Moreover, in contrast to many cancers that have been decreasing over the last decade, the incidence appears to be increasing (3) (4) (5) . Although the cornerstone of treatment for carcinoid tumors is surgery, oncogenic pathways such as various growth factor receptors and mammalian target of rapamycin (mTOR) have been implicated in the pathogenesis of carcinoid tumors and recently evaluated as therapeutic targets (2, 6) .
The Wnt/β-catenin signaling involved in early development and tissue maintenance of adults is accomplished via regulation of a specific set of genes implicated in cell proliferation and differentiation (7, 8) . This signaling leads to stabilization of β-catenin, which activates T-cell factor/lymphoid enhancer-binding factor (TCF/LEF)-dependent transcription of its target genes (9) . Hyperactivation of this pathway has been implicated in numerous malignancies (7, 9) . Adenomatous Polyposis Coli (APC) and β-catenin mutations, as well as altered expression of the pathway components, represent important mechanisms underlying activation of Wnt/β-catenin signaling (8) (9) (10) .
Wnt antagonists, including members of the 'destruction complex' for β-catenin (APC and Axin-2), are commonly mutated and demonstrate a high frequency of aberrant promoter methylation (10) (11) (12) (13) . In addition, epigenetic silencing of extracellular Wnt inhibitors, such as secreted Frizzled-related proteins (SFRPs), Wnt inhibitory factor-1 (WIF-1) and DICKKOPFs (DKKs) may contribute to the stabilization and accumulation of β-catenin in cancers with or without mutational activation of Wnt/β-catenin signaling (14) (15) (16) (17) (18) (19) (20) (21) .
Similar to promoter methylation, histone modifications also play critical roles in transcriptional regulation (22) . While histone acetylation and arginine methylation of histone H3 and H4 are related to transcriptional activation, methylation of histones may be associated with active or repressive transcriptional activity depending on the methylation site (22, 23) . Among them, methylation of histone H3 lysine 9 is a well-characterized modification (24, 25) , which is regulated by histone lysine methyltransferases including G9a and results in repression of the tumor suppressors (e.g. DSC-3 and MASPIN) in breast cancer (26) and RUNX-3 in gastric cancer (27) .
Although a high frequency of cytoplasmic accumulation and/or nuclear translocation of β-catenin has been described previously in carcinoid tumors, its correlation with mutational activation of proteins in this cascade, as well as with localization of β-catenin, is controversial (28, 29) . In our current study, we analyzed accumulation of β-catenin in the cytoplasm and/or nucleus and identified mutations of β-catenin and APC in NET cell lines and clinical tissues. We also demonstrated that transcriptional silencing of typical negative regulators of the Wnt/β-catenin pathway occurred by DNA methylation or histone modification of their promoters in NET cell lines, mainly BON that was established and characterized in our laboratory and has been widely used as a unique model of carcinoid cell biology (30) . Finally, we showed that restoration of the Wnt inhibitory genes such as SFRP-1 and WIF-1 resulted in tumor suppressor functions both in vitro and in vivo.
Materials and methods

Materials
Expression vectors (pcDNA3.1His, Invitrogen, Carlsbad, CA) for SFRP-1 and DKK-1 (18) were kindly provided by Dr Hiromu Suzuki (Department of Biochemistry, Sapporo Medical University, Japan). Other vectors in this study included TOPA TA cloning vector from Invitrogen, TCF/LEFresponsive reporter (TOPFlash) and Renilla luciferase reporter from Promega (Madison, WI). All kinds of DNA and RNA isolation kit and HotStarTaq DNA Polymerase were purchased from Qiagen (Valencia, CA). MethylCode™ Bisulfite Conversion Kit, Platinum® Pfx DNA Polymerase, Lipofectamine™ 2000 and NuPAGE® 4-12% Bis-Tris gels were obtained Abbreviations: 5-aza-CdR, 5-aza-2ʹ-deoxycytidine; ChIP, chromatin immunoprecipitation; DKK, DICKKOPF; GI, gastrointestinal; H3K9me2, dimethylation of histone H3 at lysine 9; MSP, methylation-specific PCR; NET, neuroendocrine tumor; (q)RT-PCR, (quantitative) reverse transcriptonpolymerase chain reaction; SD, standard deviation; SFRP, secreted Frizzledrelated protein; TCF/LEF, T-cell factor/lymphoid enhancer-binding factor; WIF-1, Wnt inhibitory factor-1.
from Invitrogen. A High-Capacity cDNA Reverse Transcription Kit was acquired from Applied Biosystems (Foster City, CA) and iQ SYBR-green Supermix for quantitative reverse transcription-polymerase chain reaction (qRT-PCR) and Sequi-Blot™ PVDF membranes for western blotting were purchased from Bio-Rad (Irvine, CA). A β-catenin antibody was obtained from BD Biosciences (San Jose, CA). The antibody for β-actin and cell lysis buffer were purchased from Cell Signaling (Danvers, MA). Antibodies against active-β-catenin, histone H3, dimethylated at lysine 9 (H3K9me2) and G9a and Chromatin Immunoprecipitation (ChIP) Assay Kit were acquired from Millipore (Bedford, MA). The anti-c-Myc and anti-DKK-1 antibodies were purchased from Epitomics (Burlingame, CA) and Santa Cruz Biotechnology (Santa Cruz, CA), respectively. All other antibodies were obtained from Abcam (Cambridge, MA). ECL™ western blotting detection reagents were purchased from GE Healthcare (Buckinghamshire, UK). Cell Death Detection ELISA plus kit for apoptosis assays was acquired from Roche (Indianapolis, IN) and Dual-Luciferase® Reporter Assay System for luciferase assay was purchased from Promega. UNC0638, a potent G9a inhibitor (31), was obtained from Cayman Chemical (Ann Arbor, MI). All other reagents including 5-aza-2′-deoxycytidine (5-azaCdR) were purchased from Sigma (St Louis, MO).
Immunohistochemistry
Paraffin-embedded tissue blocks of carcinoid tumors from colon (n = 1), small bowel (n = 11), lung (n = 6) and thymus (n = 2) were sectioned (5 μm) and deparaffinized in xylene and rehydrated in a descending ethanol series. Immunostaining with β-catenin antibody was performed as described previously (32) . Assessment of the stained slides was performed blindly by an experienced pathologist.
Cell culture
The human pancreatic carcinoid cell line BON (30) is cultured in Dulbecco's modified Eagle's medium and F12K in a 1:1 ratio supplemented with 5% fetal bovine serum. QGP-1 (pancreatic somatostatinoma cell line) purchased from Japan Health Sciences Foundation (Osaka, Japan) and NCI-H727 and UMC-11 cells (lung carcinoid tumor cell lines) obtained from ATCC (Manassas, VA) are maintained in RPMI 1640 medium with 10% fetal bovine serum.
Direct DNA sequence analysis
To screen for mutations in exon 3 of β-catenin or in a mutation cluster region in exon 15 of APC, genomic DNA extracted from cell lines or paraffin-embedded tissues was amplified by PCR. For APC, primer sets designed for screening codons 1231-1623 of APC were used. The primer sequences for β-catenin and APC are listed in Supplementary Table 1, available at Carcinogenesis Online. The PCR products were purified from agarose gels and were confirmed by direct sequence analyses using both forward and reverse primers.
RNA isolation, reverse transcription-polymerase chain reaction and qRT-PCR analysis
Total RNA was isolated from cultured cells using RNeasy kits (Qiagen) according to the manufacturer's instructions. Reverse transcription-polymerase chain reaction (RT-PCR) analysis of SFRP-1, Axin-2, DKK-1, DKK-3 and WIF-1 expression was performed using cDNA synthesized from 1 µg of total RNA and the primers listed in Supplementary Table 1, available at Carcinogenesis Online. The PCR products were analyzed on a 2% agarose gel. qRT-PCR was performed using iCycler with the iQ SYBRgreen Supermix (Bio-Rad) and the same gene-specific primers; β-actin was used as an internal control (33) . The relative quantity of the transcripts was calculated by the formula 2 −ΔΔCt , where ΔCt was determined by subtracting the average β-actin Ct value from the average target Ct value.
Methylation analysis
Methylation of 5′ regions of Wnt inhibitor genes was analyzed using methylation-specific PCR (MSP) and bisulfite sequencing analysis. Briefly, PCR was performed using bisulfite-modified genomic DNA and the primers listed in Supplementary Table 1, available at Carcinogenesis Online. For MSP, primer sets that distinguish between unmethylated (U) and methylated (M) DNA were used. The PCR products were visualized by 2% agarose gel. For bisulfite sequencing, PCR products were cloned into the TOPO TA cloning vector (Invitrogen) and the plasmids from individual bacterial colonies were sequenced using both side primers.
Chromatin immunoprecipitation analysis
ChIP analysis was performed according to the manufacturer's protocol (Millipore). Purified DNA from cells incubated with 5-aza-CdR was then amplified across the DKK-1, DKK-3 and WIF-1 promoter region (Supplementary Table 1 , available at Carcinogenesis Online). The relative quantity of the transcripts for DKK-1 and WIF-1 by real-time PCR was calculated by the formula 2 −ΔΔCt , where ΔCt was determined by subtracting the average β-globin Ct value from the average target Ct value. The quantitation of DKK-3 was performed using gel-based PCR on a 2% agarose gel.
Western blot, cell proliferation and apoptosis analyses
Western blot, cell proliferation and apoptosis analyses were performed with the materials in this study as described previously (34) .
Luciferase reporter assays BON cells were plated in 24-well plates and transiently transfected with the TOPFlash reporter (0.4 μg) and the Renilla luciferase reporter (0.05 μg) with or without pcDNA3.1His vectors containing Wnt inhibitors (0.4 μg each) used previously (18) . For construction of the expression vector for WIF-1, the complete open reading was produced by PCR from the WIF-1 cDNA clone (OriGene Technologies, Rockville, MD) using specified primers (Supplementary Table 1 , available at Carcinogenesis Online). Transfections were performed using Lipofectamine™ 2000 according to the manufacturer's instructions (Invitrogen). For UNC0638 treatment, varying concentrations of UNC0638 were treated into BON cells after 1 day. The cells were harvested and luciferase activity was measured 2 days after transfection.
Colony formation assay BON cells (1 × 10
6 cells) were transfected with 10 μg of each Wnt inhibitor or empty vector by electroporation using GenePulser XCell (Bio-Rad). Cells were then plated in 6-well plates and selected for 2-3 weeks with G418 (0.8 mg/ml). Colonies were then stained with crystal violet solution and imaged using the Alpha Innotech Imaging system and counted using the AlphaEaseFC™ software (Alpha Innotech Corporation, San Leandro, CA).
Soft agar assay
To measure anchorage-independent growth, BON cells were plated in growth medium containing 0.4% agarose in 6-well plates at a concentration of 2.5 × 10 5 cells per well onto a bottom layer of solidified 0.8% agarose. After incubation for 4 weeks, colonies were stained with crystal violet solution and quantified using AlphaEaseFC™ software. We also assessed colony size and dispersion using a Nikon TE2000 inverted microscope and NIS Elements AR3.10 software (Nikon, Melville, NY).
Tumor growth in nude mice BON cells (5 × 10
6 ) stably transfected with empty vector or SFRP-1 were collected in 100 μl of sterile phosphate-buffered saline and inoculated subcutaneously into 6-week-old male athymic nude mice (n = 5 per group). After 3 weeks, the tumor size was measured with a vernier caliper and the tumor volume was defined as (longest diameter) × (shortest diameter) 2 /2. All animal procedures were performed in the nude mouse facility using protocols approved by the Institutional Animal Care and Use Committee.
Statistical analysis
Descriptive statistics including mean and standard deviation (SD) were calculated and bar graphs generated to summarize the results for respective experiments. Within each experiment, comparisons between two groups were performed using two-sample t-tests, whereas comparisons across groups were accomplished using one-way analysis of variance models and test for linear trend of increasing dose levels or pairwise comparisons with control group were subsequently performed using contrast statements. Estimates of mutation rates in cell lines and carcinoid tissues were calculated along with exact 95% confidence intervals, whereas tests whether mutation proportions were significantly different from the null value of 0 were performed using the binomial test. Normality assumptions of the analysis of variance and two-sample t-tests for each outcome were assessed. P-values < 0.05 were considered statistically significant.
Results
Analysis of β-catenin localization and mutation of β-catenin and APC in NETs
To examine Wnt/β-catenin signaling status in NETs, we first assessed β-catenin localization in clinical NET tissues (i.e. lung, thymus and GI carcinoids) since it is well known that activation of this pathway results in the localization of β-catenin in the cytoplasm and/ or nucleus. In the normal epithelium of the colon, ileum and other organs, β-catenin staining was mainly localized to the cell membrane as reported previously (28) (data not shown). In 75% of the clinical samples (11 of 12 GI carcinoids and 4 of 6 lung carcinoids), there was membranous but not cytoplasmic or nuclear staining, similar to that of normal epithelium ( Figure 1A, upper) . In 15% cases (1 of 12 GI carcinoids and 2 of 6 lung carcinoids), cytoplasmic and membranous staining was detected ( Figure 1A , middle), whereas nuclear and cytoplasmic staining was observed in two carcinoid tumors of the thymus ( Figure 1A, bottom) . Activation of Wnt/β-catenin signaling was confirmed in the NET samples demonstrating both cytoplasmic + membranous and nuclear + cytoplasmic staining, although there was variability in the degree of activation.
Next, we examined mutations in exon 3 of β-catenin and a mutation cluster region in exon 15 of APC in 4 NET cell lines and the 20 clinical NET samples. As shown in Figure 1B , a missense mutation (I35S) of β-catenin was identified in a thymus carcinoid tumor, which resulted in replacement of the Ile (ATC) at codon 35 by Ser (AGC); β-catenin accumulation in the cytoplasm and nucleus was observed ( Figure 1A, bottom) , and there appeared to be a correlation between accumulation of β-catenin and β-catenin mutation. In contrast, no β-catenin mutations were detected in the other NET cells and clinical samples. Moreover, a missense mutation containing a Glu (GAA) to Gln (CAA) substitution at codon 1317 (E1317Q) in the APC was identified in BON cells ( Figure 1C , upper) but was not noted in the other samples. We also found a silent mutation (T1493T) of APC where the ACG at codon 1493 was replaced by ACA in BON cells ( Figure 1C , bottom). The same silent mutation of APC was noted in QGP-1 and NCI-H727 cells and in NET tissue samples including all GI carcinoid tumors ( Figure 1D ). Estimates of silent mutation rates and 95% exact binomial confidence intervals for NET cell lines and clinical samples were 0.75 (3/4) and 95% CI: 0.19, 0.99 and 0.9 (18/20) and 95% CI: 0.68, 0.99, respectively. Based on the binomial test, each P-value for both specimens testing whether the mutation proportion is significantly different from 0 was noted to be statistically significant (P < 0.0001).
Negative regulators of the Wnt/β-catenin pathway are re-expressed by 5-aza-CdR treatment in BON cells
In addition to mutations of APC and β-catenin, the aberrant activation of Wnt/β-catenin signaling can also be achieved by silencing of inhibitory genes for the pathway (11, (13) (14) (15) (16) (17) (18) (19) (20) (21) . To determine whether the silencing of negative regulators of the pathway was due to methylation, we treated BON, the most extensively utilized NET cells, with the DNA methyltransferase inhibitor, 5-aza-CdR, and examined the expression of representative Wnt/β-catenin signaling inhibitors, SFRP-1, Axin-2, DKK-1, DKK-3 and WIF-1 using RT-PCR (Figure 2A) . We found that treatment with 5-aza-CdR (either 0.5 or 5 µM) restored the expression of Wnt inhibitor genes. To confirm these results, mRNA expression levels were also investigated by qRT-PCR ( Figure 2B ). Incubation of cells with 5-aza-CdR (0.5 μM) resulted in a significant induction of all tested genes (6.2-fold for SFRP-1; 5.2-fold for Axin-2; 11.4-fold for DKK-1; 2.7-fold for DKK-3 and 4.7-fold for WIF-1). The effects were more pronounced after treatment with 5 μM 5-aza-CdR, suggesting that Wnt inhibitor genes were the targets of epigenetic silencing through methylation in BON cells.
The CpG islands in the 5′ regions of SFRP-1 and Axin-2 are hypermethylated in NET cells and the methylation of SFRP-1 is highly associated with in clinical NET tissues
To determine whether the induction of expression of the aforementioned Wnt/β-catenin signaling pathway inhibitors by 5-aza-CdR was due to CpG island methylation, we examined the methylation status of the 5′ regions of these genes using MSP analysis and bisulfite sequencing in four NET cell lines. MSP analysis using two MSP primer pairs revealed methylation of the 5′ region of SFRP-1 in all of the tested cell lines ( Figure 3A) . The methylation profile of CpG sites in the 5′ region of SFRP-1 was further analyzed in BON and QGP-1 cells by bisulfite sequencing ( Figure 3B ). Whereas complete methylation was noted in QGP-1 cells, the CpG islands of SFRP-1 were partially methylated in BON cells. Moreover, the promoter of Axin-2 was also methylated in these four NET cells as noted by MSP analysis ( Figure 3A) . Bisulfite sequencing of BON and QGP-1 cells confirmed hypermethylation of the CpG islands consistent with the MSP data ( Figure 3C ). Based on the above findings, we further investigated CpG island methylation of SFRP-1 and Axin-2 in the same NET patients' samples used in immunohistochemical and mutational analyses. Aberrant CpG site methylation of SFRP-1 was observed in almost all NET samples by MSP using the two primer pairs but in only one GI carcinoid (p12), the methylation of Axin-2 was shown ( Figure 3D ). These data demonstrated that silencing of SFRP-1 and Axin-2 expression was linked with DNA methylation in NET cell lines and methylation of SFRP-1 was strongly associated with clinical NET tissues especially.
Repression of unmethylated Wnt inhibitor genes is associated with the level of H3K9me2
The CpG island methylation status of the DKK-1, DKK-3 and WIF-1 was also tested using both MSP analysis ( Figure 4A In addition to DNA demethylation, 5-aza-CdR is also associated with H3K9 demethylation in the regulatory regions of silenced genes (26, 35, 36) . In particular, induction of the silenced genes such as two antimetastatic tumor suppressor genes, DSC-3 and MASPIN, in breast cancer (26) and RUNX-3 in gastric cancer (27) by treatment with 5-azaCdR was closely associated with significant decreases of H3K9me2 in the promoters. To examine whether H3K9me2 was involved in expression of the above genes, we performed ChIP analyses with an 
Suppression of TCF/LEF transcriptional activity and cell growth by Wnt inhibitor gene expression in BON cells
To examine the relationship between the silencing of Wnt inhibitors and the Wnt/β-catenin signaling activity, we transiently cotransfected BON cells with a TOPFlash and the Wnt inhibitor genes showing repressed expression. TCF/LEF activity was significantly suppressed by overexpression of the respective genes (0.4-fold for SFRP-1, 0.6-fold for WIF-1 and 0.3-fold for DKK-1) compared with empty vector ( Figure 5A ). Furthermore, in order to determine the effect of these genes in regulating growth, we expressed the Wnt inhibitors in BON cells and then assessed for colony formation ( Figure 5B ). After transfection and selection with G418, we found that introduction of these inhibitors markedly suppressed colony formation (51% for SFRP-1, 57% for WIF-1 and 41% for DKK-1) ( Figure 5C ). Overexpression of DKK-3 also diminished the TCF/LEF activity (0.8-fold) and colony formation (37%) compared with empty vector (Supplementary Figure 5 , available at Carcinogenesis Online). Taken together, these results demonstrate that Wnt inhibitor genes, silenced in BON cells, can inhibit Wnt/β-catenin signaling activity and suppress tumor cell growth.
Tumor suppressor effects of SFRP-1 and WIF-1 in BON cells
Next, we established and selected BON cell clones demonstrating high levels of SFRP-1 ( Figure 6 ) or WIF-1 (Supplementary Figure 6 , available at Carcinogenesis Online) following G418 selection. Reporter assays using TOPFlash showed significant reduction of the transcriptional activity in both SFRP-1 stable cells compared with control cells stably transfected with the empty vector ( Figure 6A) . Expression of SFRP-1 decreased the levels of active-β-catenin, which recognizes the active, dephosphorylated form of β-catenin on Ser37 or Thr41, and c-Myc ( Figure 6B) . Additionally, to determine the effect of SFRP-1 expression on anchorage-independent growth, we performed soft agar assays using the stable transfectants. The numbers of colonies in cells stably expressing SFRP-1 were significantly lower than those of control cells ( Figure 6C) .
Moreover, the size of colonies in the SFRP-1 clones was relatively small compared with those of control cells ( Figure 6D ). Finally, to investigate the effect of SFRP-1 on tumor growth in vivo, we injected the stable BON cell clones subcutaneously into the flanks of athymic nude mice and assessed growth. After 3 weeks, tumor growth was significantly reduced in mice injected with the SFRP-1-overexpressing BON cell clones ( Figure 6E) . Similarly, reduction of reporter activity and expression of the active form of β-catenin and c-Myc and suppression of anchorage-independent growth were shown in WIF-1-overexpressing BON cells (Supplementary Figure 6 , available at Carcinogenesis Online). Collectively, these results demonstrate that restoration of Wnt antagonists, particularly SFRP-1 and WIF-1, reduces TCF/LEF activity, expression of active-β-catenin and c-Myc and tumor growth in vitro and in vivo implying a tumor suppressor function for the Wnt inhibitor genes in NET cells.
Discussion
Accumulation of β-catenin in the cytoplasm and/or nucleus activates the transcription of Wnt target genes associated with cell proliferation and survival and is linked to human diseases including a variety of cancers (7, 8) . β-Catenin accumulation has been observed in GI carcinoid tumors (28, 29) , but the precise molecular mechanisms and functional consequences of Wnt/β-catenin pathway alterations have not been delineated. In the present study, we found that gene mutations (β-catenin and APC) and/or repression of Wnt inhibitors through epigenetic silencing by promoter methylation (SFRP-1 and Axin-2) or histone modification, H3K9me2 (DKK-1, DKK-3 and WIF-1), lead to aberrant Wnt/β-catenin signaling in NET samples, providing multiple mechanisms for the deregulation of this pathway in NETs.
First, we determined β-catenin localization in 20 NET clinical specimens and assessed mutational status of β-catenin and APC in the NET cells and tissue samples. Compared with previous reports (28, 29) , the frequency of cytoplasmic and/or nuclear localization of β-catenin in GI carcinoids was low (8.3%; 1 out of 12). In addition, only membranous β-catenin expression has been reported previously in non-GI carcinoid tumors (29) ; however, in our study, two of six lung and all thymus carcinoids demonstrated cytoplasmic and/ or nuclear staining of β-catenin. The missense mutation (I35S) of β-catenin detected in a thymus carcinoid abrogates the phosphorylation-dependent interaction of β-catenin, resulting in activation of the Wnt/β-catenin signaling pathway (38) . Previously, this mutation was noted to be infrequent and mainly identified in hepatocellular carcinoma (39) . Besides, in BON cells, we found an APC missense mutation (E1317Q) which, although controversial, has been reported as a colorectal cancer risk associated allele (40) (41) (42) . A silent mutation (T1493T) of APC was also detected and confirmed to be statistically significant in 75% of NET cell lines and 90% of the clinical samples. This silent alteration has been detected previously as a frequent neutral polymorphism identified in numerous types of tumors (43, 44) . Together, alteration in Wnt/β-catenin signaling could be detected in both GI and non-GI carcinoid tumors and mutations of β-catenin and APC are infrequent but may be a factor in the pathogenesis of NETs, albeit in a relatively small sample size.
It is becoming increasingly evident that the aberrant activation of Wnt/β-catenin signaling can also be achieved by the epigenetic silencing of the Wnt inhibitors that are also regulated by β-catenin/ TCF complex as components of a negative feedback loop (7, 9) . We demonstrated minimal to no expression of the Wnt inhibitors, SFRP-1, Axin-2, DKK-1, DKK-3 and WIF-1 in the BON cell line. However, expression of these Wnt inhibitor genes increased after treatment with 5-aza-CdR, indicating that Wnt inhibitor genes are the targets of epigenetic silencing through methylation. The mechanism for downregulation of the Wnt antagonists in cancers is predominately due to silencing by promoter hypermethylation (10) ; indeed, we demonstrated that silencing of SFRP-1 and Axin-2 was associated with their promoter hypermethylation in all NET cell lines and that the methylation of SFRP-1 was strongly associated with the majority of carcinoid tumor tissues although cytoplasmic and/or nuclear staining of β-catenin was not detected in all of the tumors. Promoter methylation of Wnt inhibitors provides a reliable assessment of prognosis in a number of cancers. For example, aberrant promoter methylation of SFRP-1 was associated with an overall shorter survival in patients with breast cancers (45) , WIF-1 methylation is a poor prognostic factor for patients with acute myeloid leukemia (AML) (46) and DKK-3 methylation is an independent prognostic marker for gastric cancers (20) . Therefore, methylation of SFRP-1 alone may not be sufficient to deregulation of Wnt/β-catenin signaling but portend a prognosis in patients with NETs.
Whereas DKK-1, DKK-3 and WIF-1 are silenced by DNA methylation in most tumor cells, the promoters of these genes were found to be unmethylated despite increased expression with 5-aza-CdR treatment in NET cells. Recently, it has been shown that treatment with 5-aza-CdR is associated with histone H3K9 demethylation in some silenced genes (26, 35, 36) . Moreover, histone modification, including H3K9me2, occurred with silencing of a tumor suppressor gene p16
INK4a (47) . Also, epigenetic repression of DACT3, which is another negative Wnt regulator in colon cancer, is associated with histone modifications instead of promoter hypermethylation (48) . Here, we show that, in the case of DKK-1, DKK-3 and WIF-1 in NET cells, epigenetic silencing occurs through repressive histone modification, H3K9me2, and does not involve or require methylation of the promoter. Using a novel G9a inhibitor, UNC0638, we further elucidated that the silencing of the Wnt inhibitors is allowed by H3K9me2 and inhibition of proliferation by UNC0638 is closely related with reduction of Wnt/β-catenin signaling and induction of apoptosis in BON cells. Previously, G9a was reported to be required for the maintenance of the malignant phenotype and that elevated expression of G9a, which is associated with poor prognosis, promotes invasion and metastasis in lung cancer (49) . Moreover, knockdown of G9a induces cell apoptosis; overexpression of this protein is noted in all types of cancers analyzed (50) . G9a attenuates the expression (26) and activity (50) of tumor suppressor genes, suggesting this protein may promote tumor cell properties. In line with the above evidences, our findings suggest that G9a may also be involved in NET tumorigenesis by regulating H3K9me2.
Finally, we examined whether restoration of Wnt antagonists, which are silenced in NET cells, would have tumor suppressive effects in the BON cell line. Silencing of various Wnt inhibitor genes and downregulation of their expression have been reported in many cancer types; induction of their expression leads to tumor suppression (11, (13) (14) (15) (16) (17) (18) (19) (20) (21) . In this regard, we also confirmed that induction of Wnt antagonists exerts a tumor suppressive effect in BON cells further indicating that epigenetic silencing of these Wnt inhibitors contribute to NET tumorigenesis. Further work is required to elucidate the correlation or connection between the deregulated Wnt/β-catenin pathway and genetic abnormalities for the components of other pathways such as PI3K/Akt/mTOR and Ras/Raf/MAPK signaling, which are also important in NET functions.
In summary, our findings suggest that the aberrant Wnt/β-catenin signaling through epigenetic silencing of Wnt negative regulatory genes or infrequent gene mutation contributes to NET pathogenesis and growth. Assessment of the methylation status of Wnt inhibitors, especially SFRP-1, may be used as a prognostic indicator and to identify patients with NETs who would most likely benefit from a treatment regimen to include Wnt inhibitors or G9a inhibitors.
Supplementary material
Supplementary Table 1 and Figures 1-6 can be found online at http:// carcin.oxfordjournals.org/ 
